This is the current release of the guideline.

Definitions of the strength of the recommendations (A, B, C, U) and classification of the evidence (Class I through Class IV) are provided at the end of the "Major Recommendations" field.

1. Settings in which transcranial Doppler ultrasonography (TCD) is able to provide information and in which its clinical utility is established.
   1. Screening of children aged 2 to 16 years with sickle cell disease for assessing stroke risk (Type A, Class I), although the optimal frequency of testing is unknown (Type U).
   2. Detection and monitoring of angiographic vasospasm (VSP) spontaneous subarachnoid hemorrhage (sSaH) (Type A, Class I-II). More data are needed to show if its use affects clinical outcomes (Type U).
2. Settings in which TCD is able to provide information, but in which its clinical utility, compared with other diagnostic tools, remains to be determined.
   1. Intracranial steno-occlusive disease. TCD is probably useful (Type B, Class II to III) for the evaluation of occlusive lesions of intracranial arteries in the basal cisterns (especially the internal carotid artery [ICA] siphon and middle cerebral artery [MCA]). The relative value of TCD compared with magnetic resonance angiography (MRA) or computed tomography angiography (CTA) remains to be determined (Type U). Data are insufficient to recommend replacement of conventional angiography with TCD (Type U).
   2. Cerebral circulatory arrest (adjunctive test in the determination of brain death). If needed, TCD can be used as a confirmatory test, in support of a clinical diagnosis of brain death (Type A, Class II).
3. Settings in which TCD is able to provide information, but in which its clinical utility remains to be determined.
   1. Cerebral thrombolysis. TCD is probably useful for monitoring thrombolysis of acute MCA occlusions (Type B, Class II to III). More data are needed to assess the frequency of monitoring for clot dissolution and enhanced recanalization and to influence therapy (Type U).
   2. Cerebral microembolism detection. TCD monitoring is probably useful for the detection of cerebral microembolic signals in a variety of cardiovascular/cerebrovascular disorders/procedures (Type B, Class II to IV). Data do not support the use of this TCD technique for diagnosis or monitoring response to antithrombotic therapy in ischemic cerebrovascular disease (Type U).
   3. Carotid endarterectomy (CEA). TCD monitoring is probably useful to detect hemodynamic and embolic events that may result in perioperative stroke during and after CEA in settings where monitoring is felt to be necessary (Type B, Class II to III).
   4. Coronary artery bypass graft (CABG) surgery. TCD monitoring is probably useful (Type B, Class II to III) during CABG for detection of cerebral microemboli. TCD is possibly useful to document changes in flow velocities and carbon dioxide (CO₂) reactivity during CABG surgery (Type C, Class III). Data are insufficient regarding the clinical impact of this information (Type U).
   5. Vasomotor reactivity (VMR) testing. TCD is probably useful (Type B, Class II to III) for the detection of impaired cerebral hemodynamics in patients with severe (>70%) asymptomatic extracranial ICA stenosis, symptomatic or asymptomatic extracranial ICA occlusion, and cerebral small-artery disease. Whether these techniques should be used to influence therapy and improve patient outcomes remains to be determined (Type U).
   6. VSP after traumatic subarachnoid hemorrhage (tSAH). TCD is probably useful for the detection of VSP following tSAH (Type B, Class III), but data are needed to show its accuracy and clinical impact in this setting (Type U).
   7. Transcranial color-coded sonography (TCCS). TCCS is possibly useful (Type C, Class III) for the evaluation and monitoring of space-occupying ischemic middle cerebral artery (MCA) infarctions. More data are needed to show if it has value vs. computed tomography (CT) and magnetic resonance imaging (MRI) scanning and if its use affects clinical outcomes (Type U).
4. Settings in which TCD is able to provide information, but in which other diagnostic tests are typically preferable.
   1. Right-to-left cardiac shunts. Whereas TCD is useful for detection of right-to-left cardiac and extracardiac shunts (Type A, Class II), transesophageal echocardiography (TEE) is superior, as it can provide direct information regarding the anatomic site and nature of the shunt.
   2. Extracranial ICA stenosis. TCD is possibly useful for the evaluation of severe extracranial ICA stenosis or occlusion (Type C, Class II to III), but, in general, carotid duplex and magnetic resonance angiography (MRA) are the diagnostic tests of choice.
   3. Contrast-enhanced TCCS. (Contrast-enhanced) TCCS may provide information in patients with ischemic cerebrovascular disease and aneurismal subarachnoid hemorrhage (aSAH) (Type B, Class II to IV). Its clinical utility vs. CT scanning, conventional angiography, or nonimaging TCD is unclear (Type U).

Definitions:

Rating of Recommendations

A = established as useful/predictive or not useful/predictive for the given condition in the specified population.

B = probably useful/predictive or not useful/predictive for the given condition in the specified populations.

C = possibly useful/predictive or not useful/predictive for the given condition in the specified population.

D = data inadequate or conflicting. Given current knowledge, test/predictor unproven.

U = data inconclusive.

Translation of Evidence to Recommendations

Level A rating requires >1 convincing Class I or >2 consistent, convincing Class II studies.

Level B rating requires >1 convincing Class II or >3 consistent Class III studies.

Level C rating requires >2 convincing and consistent Class III studies.

Rating of Diagnostic Article

Class I: Evidence provided by prospective study in broad spectrum of persons with suspected condition, using a "gold standard" to define cases, where test is applied in blinded evaluation, and enabling assessment of appropriate tests of diagnostic accuracy.

Class II: Evidence provided by prospective study in narrow spectrum of persons with suspected condition or well-designed retrospective study of broad spectrum of persons with suspected condition (by "gold standard") compared with broad spectrum of controls where test is applied in blinded evaluation and enabling assessment of appropriate tests of diagnostic accuracy.

Class III: Evidence provided by retrospective study where either persons with established condition or controls are of narrow spectrum and where test is applied in blinded evaluation.

Class IV: Any design where test is not applied in blinded fashion or evidence provided by expert opinion or descriptive case series.

Rating of Prognostic Article

Class I: Evidence provided by prospective study in broad spectrum of persons who may be at risk of outcome (target disease, work status). Study measures predictive ability using independent gold standard to define cases. Predictor is measured in evaluation masked to clinical presentation. Outcome is measured in evaluation masked to presence of predictor.

Class II: Evidence provided by prospective study of narrow spectrum of persons who may be at risk for having the condition, retrospective study of broad spectrum of persons with condition compared with broad spectrum of controls. Study measures prognostic accuracy of risk factor using acceptable independent gold standard to define cases. Risk factor is measured in evaluation masked to the outcome.

Class III: Evidence provided by retrospective study where persons with condition or controls are of narrow spectrum. Study measures predictive ability using independent gold standard to define cases. Risk factor measured in evaluation masked to outcome.

Class IV: Any design where predictor is not applied in masked evaluation or evidence by expert opinion, case series.

None provided

The type of supporting evidence is identified and graded for each recommendation (see "Major Recommendations").

Not applicable: The guideline was not adapted from another source.

2004 May 11

American Academy of Neurology - Medical Specialty Society

American Academy of Neurology (AAN)

Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

American Academy of Neurology (AAN) Therapeutics and Technology Assessment Subcommittee Members: Douglas S. Goodin, MD (chair); Yuen T. So, MD, PhD (vice-chair); Carmel Armon, MD, MHS; Richard M. Dubinsky, MD; Mark Hallett, MD; David Hammond, MD; Chung Y. Hsu, MD, PhD; Andres M. Kanner, MD; David Lefkowitz, MD; Janis Miyasaki, MD; Michael A. Sloan, MD, MS; James C. Stevens, MD

Not stated

This is the current release of the guideline.

None available

This NGC summary was completed by ECRI on August 17, 2004. The information was verified by the guideline developer on September 9, 2004.

This NGC summary is based on the original guideline, which is copyrighted by the American Academy of Neurology.